Abstract
Crizotinib is a tyrosine kinase inhibitor (TKI), which is a target for echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK). It can prolong the progression free survival (PFS) of ALK positive patients with advanced non-small cell lung cancer (NSCLC). The median PFS in the first-line and second-line mPFS is 10.9 months and 7.7 months. However, despite an initial benefit, patients inevitably experience tumor progression, due to the ALK fusion gene amplification and secondary mutations of ALK kinase domain. Clinical trials show the promising efficacy like next generation ALK inhibitors and heat shock protein 90 (HSP90) can overcome acquired resistance. Key words: Lung neplasms; Drug resistance, neoplasm; Therapy
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
